---
title: "NSCLC"
date: "2023-12-05 09:57:35"
enableToc: false
tags:
  - building
---

> [!info]
>
> 🌱來自: [[snippets]]

# NSCLC

Non-smoker/smoker, female/male, Asian

### NSCLC, M/D? adenocarcinoma, in LLL, cTxNxMx, stage IV, with ?? mets, dx on 2020/00/00

\*EGFR exon 21 L858R/ 19 Del/ Wild type, ALK, ROS-1, PDL-1

- Initial presentation:
- Follow up parameter: Primary lung CT, CEA if elevated, and bone scan
- Chest CT on 2020/00/00:
- PET CT on 2020/00/00:
- Treatment plan:
- 2020/00/00: Explain the purpose of palliative chemotherapy is to control disease and prolong life and maintain quality of life but not cure.
- 2020/00/00 Discuss treatment choice for EGFR mutated lung cancer in 1st line reimbursed by NHI such as afatinib, tarceva, or Iressa. Osimertinib has first line phase III data but only reimbursed in 19 del without brain mets.
  @ Start palliatve chemotherapy or targeted therapy on ?, explain treatment options if EGFR mutated or wild type to the patient
  @ Vascular assessment, nutritional assessment, dental check before chemotherapy, pharmacist education
  @ Check viral marker before treatment
  @ Send EGFR testing, ALK, ROS-1 if ALK negative, and PDL-1
  @ 申請重大傷病
